Semaglutide vs. Tirzepatide: What the Head-to-Head Data Actually Shows
SURMOUNT-5 gave us the first direct comparison between these two drugs. Tirzepatide won on weight loss. But cost, access, and tolerability tell a more nuanced story. Here are the numbers.
Until 2024, every comparison between semaglutide and tirzepatide was indirect — different trials, different patient populations, different endpoints. SURMOUNT-5 changed that. It's the first randomized, head-to-head trial comparing the two drugs in the same patients, over the same time period, measured the same way.
The result wasn't close.
The Trial: SURMOUNT-5
SURMOUNT-5 was a phase 3b, open-label, randomized trial conducted across 32 sites in the U.S. and Puerto Rico. It enrolled 751 adults with obesity (BMI ≥30) or overweight with at least one complication (BMI ≥27), all without type 2 diabetes. Participants were randomized to maximum tolerated doses of either tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg), administered as weekly subcutaneous injections for 72 weeks.
The trial was published in The New England Journal of Medicine in 2024. It remains the most clinically relevant comparison of these two drugs available.
Efficacy: The Numbers
| Outcome | Tirzepatide | Semaglutide |
|---|---|---|
| Mean weight loss at 72 weeks | −20.2% | −13.7% |
| Waist circumference reduction | −18.4 cm | −13.0 cm |
| Achieved ≥10% weight loss | ~82% | ~66% |
| Achieved ≥20% weight loss | ~50% | ~24% |
| Achieved ≥25% weight loss | ~35% | ~10% |
Both groups started at similar baseline weights. Both groups escalated to maximum tolerated doses. The difference was statistically significant across every endpoint measured (P < 0.001).
A post-hoc analysis published in the European Heart Journal – Open in September 2025 also found that tirzepatide was associated with greater predicted 10-year cardiovascular disease risk reduction compared to semaglutide.
Why the Difference?
The answer is pharmacological. Semaglutide is a GLP-1 receptor agonist — it mimics a single gut hormone that regulates appetite and blood sugar. Tirzepatide is a dual GLP-1/GIP receptor agonist — it targets two receptors simultaneously.
GIP (glucose-dependent insulinotropic polypeptide) receptors in fat tissue appear to regulate lipid uptake and energy expenditure. When co-activated with GLP-1 receptors, the two pathways produce synergistic effects on fat mobilization that a single-agonist drug cannot match. This dual mechanism is the leading explanation for tirzepatide's superior efficacy in clinical trials.
Side Effects: Comparable
Despite the efficacy gap, the safety profiles are remarkably similar. Both drugs carry warnings for thyroid C-cell tumors (in rodents), pancreatitis, and gallbladder disease. The most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation — and they typically improve after the first few weeks of treatment or dose escalation.
In SURMOUNT-5, adverse events were described as "generally mild to moderate" for both arms, with no new safety signals emerging for tirzepatide despite its higher potency. Discontinuation rates due to side effects were similar between groups.
Cost Comparison: 2026
Cost is where the comparison gets more complicated — and for many patients, more decisive.
| Access Channel | Semaglutide | Tirzepatide |
|---|---|---|
| Brand-name injectable (list price) | ~$999/mo | ~$1,060/mo |
| Brand-name with savings program | ~$499/mo | ~$399–549/mo |
| Oral Wegovy (semaglutide pill) | $149–299/mo | N/A |
| Foundayo / orforglipron (oral GLP-1 pill) | N/A | $149/mo starting |
| Telehealth + compounded injectable | $150–350/mo | $150–350/mo |
Semaglutide has broader insurance formulary coverage due to its longer time on market. Tirzepatide coverage is growing but often requires step therapy — meaning insurance may require trying semaglutide first. Both Novo Nordisk and Eli Lilly have launched aggressive direct-to-consumer pricing programs in 2026.
For cash-pay patients, the telehealth + compounded route remains the most affordable access point for both medications, typically ranging from $150 to $350 per month including consultation and medication.
Access Options: Where to Start
Several telehealth providers offer compounded semaglutide and tirzepatide programs with licensed medical oversight, home delivery, and bundled pricing. Below are verified providers currently accepting new patients.
Comprehensive GLP-1 weight management with licensed providers and home delivery. Semaglutide and tirzepatide programs available.
Starting from $297/mo
⚠️ Compounded medications are not FDA-approved. Paid link.
Direct intake GLP-1 programs with personalized treatment plans and ongoing clinical support.
Starting from $199/mo
⚠️ Compounded medications are not FDA-approved. Paid link.
GLP-1 treatment programs with licensed medical oversight and shipped-to-your-door convenience.
Pricing disclosed after consultation
⚠️ Compounded medications are not FDA-approved. Paid link.
Affordable direct care platform — book a GLP-1 consultation with a licensed clinician. Brand-name FDA-approved medications.
Consultations from $99
Paid link.
Tirzepatide produces more weight loss than semaglutide — the SURMOUNT-5 data is unambiguous on that point. But "more effective" doesn't automatically mean "better for you." Insurance coverage, cost, needle-free options (oral Wegovy or Foundayo), tolerability, and your prescriber's recommendation all factor in. Both drugs produce clinically meaningful weight loss that most patients would consider transformative.
Sources
- Aronne LJ, et al. Tirzepatide versus semaglutide in adults with obesity: SURMOUNT-5 trial. New England Journal of Medicine. 2024. nejm.org
- American College of Cardiology. SURMOUNT-5: Greater Loss of Weight, Waist Circumference With Tirzepatide Than Semaglutide. July 2025. acc.org
- Mamas MA, et al. Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction: post-hoc analysis of SURMOUNT-5. European Heart Journal – Open. September 2025. pubmed.ncbi.nlm.nih.gov
- Real-world comparative effectiveness study. Truveta EHR data. Published 2026. pmc.ncbi.nlm.nih.gov
- Eli Lilly. FDA approves Foundayo (orforglipron). Press release, April 1, 2026. investor.lilly.com
Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, clinical data, or provider selection.